Aug 2026· The Oncologist· Vol 31· 0 citations· 52 references
Medicine
TL;DR
Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship, andarse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.
Abstract
Abstract Background Overall survival (OS) in adjuvant and perioperative immunotherapy trials requires prolonged follow-up. We examined whether treatment effects on disease-free survival (DFS) and recurrence-free survival (RFS) were associated with OS at matched 2-, 3-, and 5-year windows. Methods The main analysis included 23 strict-primary randomized trials. DFS and RFS were modeled separately across 6 paired time windows using 2 co-primary trial-level approaches: a conventional OS-variance-weighted regression and a conditional errors-in-variables model accounting for uncertainty in both log-HRs. Because within-trial correlations were unavailable, ρ was varied from 0 to 0.75. Eligibility-sensitivity studies were supplementary; broad-taxonomy evidence was excluded. EFS was descriptive, PFS and PFS2 were analyzed separately, and QoL regression required at least 5 verified contrasts. Results Nineteen trials contributed 2-year same-window pairs (12 DFS; 7 RFS), 8 contributed 3-year pairs, and 5 contributed 5-year pairs. For 2-year early endpoints vs 2-year OS, weighted slopes were 0.014 (95% CI, −0.286 to 0.314) for DFS and 0.630 (95% CI, −1.243 to 2.502) for RFS. Eight of 9 fitted weighted-regression intervals included zero; the only nominally positive result involved 4 RFS trials. In errors-in-variables analyses, slopes for the largest DFS and RFS comparisons ranged from 0.011 to 0.264 and from 0.758 to 0.885, respectively, and all profile CIs included zero. Six strict-primary QoL contrasts were verified, but no window reached n = 5. Conclusion Strict-primary analyses did not demonstrate a consistent or precise early-endpoint–OS relationship. Sparse later windows and uncertainty in both treatment-effect estimates preclude surrogate validation.
623
Background:
EFS/DFS are commonly used endpoints in perioperative immune checkpoint inhibitor (ICI) trials, but their reliability as surrogates for overall survival (OS) remains uncertain. For surrogacy to be established there should be strong and consistent correlation between the surrogate and definitive e...
Haritha Gandicheruvu, A. Mittal, Manpreet Saini et al.· JCO Oncology Practice· 0 citations
Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...
J. Dai, Meng-Ni Liu, Hu Li et al.· Frontiers in Pharmacology· 0 citations
OBJECTIVE
The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate...
L. F. Costa de Almeida, A. Cappellaro, M. Noronha et al.· Journal of the National Canc...· 1 citation
BACKGROUND
The oligometastatic state is characterized by limited metastatic burden for which metastasis-directed therapy (MDT) may provide durable control. Endpoint selection in MDT trials is poorly standardized and may not reflect long-term benefit or patient priorities. We systematically reviewed clinical endpoints i...
David C. Chen, E. Khosh Kish, Seung-Min Lee et al.· The Oncologist· 0 citations
Background Immunotherapy for pediatric brain tumors has expanded rapidly, yet its effects on survival and neurologic safety remain unclear. A systematic review and meta-analysis was conducted to quantify efficacy and toxicity across immunotherapy modalities. Methods Following PRISMA 2020 guidelines, prospective pediatr...
Tomasz Tykocki· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.